An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK

Current Medical Research and Opinion

Volumn 23, Issue 4, 2007, Pages 895-901

  Palmer, Andrew J ^a,b   Valentine, William J ^a,b   Ray, Joshua A ^a,b   Foos, Volker ^a,b   Lurati, Francesco ^a,b   Smith, Inger ^c   Lammert, Morten ^c   Roze, Stéphane ^a,b  

^a IQVIA   (United States)

^b Novo Nordisk Limited ^*

^c NOVO NORDISK A S   (Denmark)

Author keywords

Costs; Human insulin; Insulin detemir, aspart; Modelling; Neutral Protamine Hagedorn (NPH) insulin; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; ISOPHANE INSULIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

ADULT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HUMANS; INSULIN; MALE; MIDDLE AGED; MODELS, ECONOMIC; PATIENT ACCEPTANCE OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS;

EID: 34247398253     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X182194     Document Type: Article

References (38)

1. The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
2. The UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
3. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993;329:977-86
4. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabetic Med 2000;17:762-70
5. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects widi Type 1 diabetes. Diabetic Med 2004;21:769-75
6. Raskin P, Gudirie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23:583-8
7. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind crossover trial in type 1 diabetes. Diabetes Care 1999;22:801-5
8. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol 2002;16:475-92
9. Hermansen K, Madsbad S, Perrild H, et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001;24:296-301
10. Russell-Jones D, Simpson R, Bolinder J, et al. Lower and more predictable fasting blood glucose and reduced risk of nocturnal hypoglycaemia with once daily insulin detemir versus NPH in subjects with type 1 diabetes. Diabetologia 2006;45:A51
11. Palmer AJ, Roze S, Valentine WJ, et al. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin 2004;20:1729-46
12. Minshall ME, Twena NS, Nicklasson L, Roze S. Long-term cost-effectiveness of insulin aspart versus soluble human insulin in patients with type 1 diabetes in the United Kingdom. Value in Health 2003;8:358-9
13. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 2004;47:622-9
14. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20:5-26
15. Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:S27-S40
16. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40
17. Harvey JN, Rizvi K, Craney L, et al. Population-based survey and analysis of trends in the prevalence of diabetic nephropathy in Type 1 diabetes. Diabetic Med 2001;18:998-1002
18. Younis N, Broadbent DM, Harding SP, Vora JR. Prevalence of diabetic eye disease in patients entering a systematic primary care-based eye screening programme. Diabetic Med 2002;19:1014-21
19. Jonsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Intern Med 2003;253:472-80
20. Benett LJ, Lambert C, Hinds G, Kirton C. Emerging standards for diabetes care from a city-wide primary care audit. Diabetic Med 1994;11:489-92
21. NICE [National Institute for Clinical Excellence]. Item 3 (b) guide to methods of technology appraisal. November 2003. Available at: www.nice.org.uk/page.aspx?o=93882 [Last accessed 6 Feb 2007]
22. James M, Turner DA, Broadbent DM, et al. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. Br Med J 2000;320:1627-31
23. Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabetic Med 2003;20:586-93
24. OMNILABS (UK) Limited, Price List, effective October 2000, London
25. Netten A, Curtis L. Unit costs of health and social care 2003. Available from: www.pssru.ac.uk/pdf/uc2003/uc2003_inflation.pdf [Last accessed 12 December 2005]
26. Monthly index of marketed medicines. March 2004. Available from: www.emims.com [Last accessed 12 December 2005]
27. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
28. index) in people with type 1 diabetes who experience severe hypoglycaemia. Diabetologia 2005;48:A292-A293
29. NICE [National Institute for Clinical Excellence]. Technology appraisal guidance - No. 53. Guidance on the use of long-acting insuiln analogues for the treatment of diabetes - insulin glargine. December 2002. Available from: www.nice.org.uk/guidance/TA53/?c=91500 [Last accessed 6 Feb 2007]
30. Morris AD, Broomhall J, Wang J, et al. Incidence of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health services resource use. Diabetes 2002;51:A75
31. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52
32. Russell-Jones D, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-36
33. Kolendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabetic Med 2006;23:729-35
34. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabetic Med 2005;22:850-7
35. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-7
36. Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetic Med 2006;23:285-92
37. Bruttomesso D, Pianta A, Crazzolara D, et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabetic Med 2002;19:628-34
38. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New Engl J Med 2005;353:2643-53